Biosceptre International is a pharmaceutical company pioneering the development of a CAR-T therapy for the treatment of a broad range of cancers.
Afon Technology has developed Glucowear, a completely non-invasive blood glucose monitor that delivers results in real-time, enhancing the take up and quality of daily management programs for diabetics.
NeedleSmart has developed a family of devices to sterilise and destroy hypodermic needles post procedure, preventing needlestick injuries and reducing disposal costs by up to 80%.
Dxcover has developed a revolutionary liquid biopsy platform with unrivalled ability to detect early-stage cancer from a simple blood sample.
Sprite IOT has developed an innovative system called SpriteGuard™ that transforms the security and customer experience of public access wi-fi users by preventing cyberattacks and providing a range of spatial analytics.
SMi has developed a transformational, new, optical technology that will have far-reaching benefits in the fields of diagnosis and drug discovery. SMi’s technology is a variant of super resolution microscopy, an area which was the subject of Nobel Prizes in 2014 and 2017.
Medical diagnosis is about to undergo a revolution based on the next generation of cheap, mass manufacturable, electrochemical sensors like those to check blood sugar levels in people with diabetes. Aureum Diagnostics is a spin-out company from the world-leading Innovation Centre at the University of Strathclyde and is based on the work of Professor Corrigan and his team.
Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk.
What are the key risks?
If you are interested in learning more about how to protect yourself, visit the FCA’s website here.